News

News

US FDA approved Holy Stone Healthcare’s application for compassionate use of CA102N in phase I clinical trials

24, Dec 2021

Holy Stone Healthcare’s new drug, CA102N, for the treatment of colorectal cancer is conducting phase I clinical trials in the US on patients with late-stage chemo-refractory mCRC. The company applied to the US FDA on November 24, 2021, for compassionate use and expanded access for the patient. The application was approved on December 21, 2021.

previous page